Skip to main navigation Skip to search Skip to main content

Standard of care for cancer-related anemia: Improving hemoglobin levels and quality of life

  • Enrico Cortesi
  • , Pere Gascón
  • , David Henry
  • , Timothy Littlewood
  • , Robert Milroy
  • , Paolo Pronzato
  • , Uwe Reinhardt
  • , Daniel Shasha
  • , Nicholas Thatcher
  • , Peter Wilkinson

    Research output: Contribution to journalArticlepeer-review

    Abstract

    The introduction of recombinant human erythropoietin (rHuEPO) has proven to be a major advance in the therapeutic options available for managing anemia in cancer patients. The results of placebo-controlled clinical trials and large, community-based, open-label studies have confirmed that epoetin alfa, a recombinant human erythropoietin, significantly reduces transfusion requirements, and reliably increases hemoglobin (Hb) levels in anemic (Hb level
    Original languageEnglish
    Pages (from-to)22-32
    Number of pages10
    JournalOncology
    Volume68
    Issue number1
    DOIs
    Publication statusPublished - 2005

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • Anemia
    • Cancer
    • Epoetin alfa
    • Fatigue
    • Quality of life

    Fingerprint

    Dive into the research topics of 'Standard of care for cancer-related anemia: Improving hemoglobin levels and quality of life'. Together they form a unique fingerprint.

    Cite this